Induced Pluripotent Stem Cells (iPSCs) refer to pluripotent stem cells with multilineage differentiation potential obtained by re-programming of terminally differentiated adult cells induced by in vitro transcription factors. Pregene has an optimized iPSCs production process, which can non-invasively obtain cells such as patient blood or urine and obtain high-quality iPSCs in a short period by re-programming, used for disease modeling, drug screening, drug development, etc. Multi-gene editing platform has achieved multiple transgene knock-in expressions to obtain therapeutic iPSCs. On this platform, Pregene masters the ability of iPSCs to differentiate into a variety of cells in vitro, by which it can produce genetically modified human cells and tissues (including various immune cells as well as islet cells, cardiomyocytes, and neuronal cells used for regenerative medicine) for the treatment of diseases.